A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms explorer™4
- Sponsors Novo Nordisk
- 03 Jul 2018 Planned primary completion date changed from 29 Aug 2018 to 20 Sep 2018.
- 26 Apr 2018 Planned End Date changed from 23 Oct 2019 to 14 Nov 2019.
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.